← Back to Clinical Trials
Recruiting NCT06842095

NCT06842095 Investigating the Effects of Transcranial Stimulation to Advance Stroke Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06842095
Status Recruiting
Phase
Sponsor University of Oxford
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-02-01
Primary Completion 2027-02-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Transcranial Alternating Current Stimulation (beta-tACS)Transcranial Alternating Current Stimulation (sham)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-02-01 with a primary completion date of 2027-02-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Non-invasive brain stimulation (NIBS) has the potential to boost rehabilitation after stroke by creating a 'pro-plastic' environment, where the brain is more adaptable in response to movement (motor) training. However, responses to classical NIBS protocols are highly variable. Movement-related changes in specific brain rhythms have previously been shown to be related to recovery of hand/arm function after a stroke. The investigators propose to use NIBS to target movement-related activity in the beta band (13-30Hz) within the motor cortical regions of the brain. The investigators will use a type of NIBS called transcranial alternating current stimulation (tACS), which uses a sinusoidally-varying electrical current where the stimulation frequency is determined to be relevant to the underlying brain rhythms of interest, and the stimulation timed to coincide with specific phases of the hand/arm movement. The primary aim is to investigate whether beta-tACS improves upper limb movement in stroke survivors.

Eligibility Criteria

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Aged 18 years or above. * Clinical diagnosis of stroke affecting the upper limb, with sufficient ability to perform the upper limb reaching task. * At least 3 months post-stroke and discharged from inpatient care. Exclusion Criteria: * Inability to follow task instructions. * Other neurological condition affecting movement (e.g. Parkinson's Disease, Multiple Sclerosis). * Standard contraindications to non-invasive brain stimulation (TMS, tACS). including (but not limited to) the presence of intracranial metallic or magnetic hardware, seizures, pregnancy, and the presence of a pacemaker or other stimulators/implants. * Insufficient verbal and written English to comprehend the study and provide informed consent.

Contact & Investigator

Central Contact

Melanie Fleming, PhD

✉ melanie.fleming@ndcn.ox.ac.uk

📞 +44 1865 611461

Principal Investigator

Charlotte J Stagg, PhD

PRINCIPAL INVESTIGATOR

University of Oxford

Frequently Asked Questions

Who can join the NCT06842095 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06842095 currently recruiting?

Yes, NCT06842095 is actively recruiting participants. Contact the research team at melanie.fleming@ndcn.ox.ac.uk for enrollment information.

Where is the NCT06842095 trial being conducted?

This trial is being conducted at Oxford, United Kingdom.

Who is sponsoring the NCT06842095 clinical trial?

NCT06842095 is sponsored by University of Oxford. The principal investigator is Charlotte J Stagg, PhD at University of Oxford. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology